Nektar Therapeutics (NKTR) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$84.16
Price Target
$132.83
Target Range
$95.00 — $185.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-8.6x
Forward PEG—
Implied Growth-8.0%
Median Target$130.50
Analyst Spread67.8%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$95
+12.9%
Consensus
$133
+57.8%
Bull Case
$185
+119.8%
NKTR Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Nektar Therapeutics (NKTR) has a Wall Street consensus price target of $132.83, based on estimates from 33 covering analysts. With the stock currently trading at $84.16, this represents a potential upside of +57.8%. The company has a market capitalization of $1.65B.
Analyst price targets range from a low of $95.00 to a high of $185.00, representing a 68% spread in expectations. The median target of $130.50 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 22 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 5 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NKTR trades at a trailing P/E of -8.6x. Analysts expect EPS to grow -8.0% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+32.0%
Avg Forward P/E16.3x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HALOHalozyme Therapeutics, Inc. | $7.8B | $65.87 | $78.33 | +18.9% | Buy | 8.2x | 27 |
 ARWRArrowhead Pharmaceuticals, Inc. | $10.5B | $74.93 | $81.22 | +8.4% | Buy | — | 20 |
 ALNYAlnylam Pharmaceuticals, Inc. | $40.2B | $301.11 | $445.67 | +48.0% | Buy | 45.0x | 52 |
 IONSIonis Pharmaceuticals, Inc. | $12.4B | $75.25 | $107.27 | +42.6% | Buy | — | 32 |
 EXELExelixis, Inc. | $11.3B | $44.42 | $45.71 | +2.9% | Buy | 13.4x | 32 |
 INCYIncyte Corporation | $19.5B | $97.47 | $109.50 | +12.3% | Buy | 13.0x | 44 |
 RCUSArcus Biosciences, Inc. | $2.6B | $26.06 | $30.00 | +15.1% | Buy | — | 18 |
 IMVTImmunovant, Inc. | $5.7B | $27.84 | $45.50 | +63.4% | Buy | — | 23 |
 CLDXCelldex Therapeutics, Inc. | $2.3B | $33.86 | $45.00 | +32.9% | Buy | — | 19 |
 AGENAgenus Inc. | $147M | $4.17 | $7.33 | +75.8% | Buy | 2.0x | 11 |
Upside Potential Comparison
AGENIMVTALNYIONSCLDXHALORCUSINCYSee NKTR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NKTR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NKTR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNKTR — Frequently Asked Questions
Quick answers to the most common questions about buying NKTR stock.
What is the NKTR stock price target for 2026?
The consensus Wall Street price target for NKTR is $132.83, representing 57.8% upside from the current price of $84.16. With 33 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is NKTR a buy, sell, or hold?
NKTR has a consensus rating of "Buy" based on 33 Wall Street analysts. The rating breakdown is predominantly bullish, with 22 Buy/Strong Buy ratings. The consensus 12-month price target of $132.83 implies 57.8% upside from current levels.
Is NKTR stock overvalued or undervalued?
NKTR's current price is $84.16 with a consensus target of $132.83 (57.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can NKTR stock go?
The most bullish Wall Street analyst has a price target of $185 for NKTR, while the most conservative target is $95. The consensus of $132.83 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover NKTR stock?
NKTR is heavily covered by Wall Street, with 33 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 22 have Buy ratings, 6 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NKTR stock forecast?
The 12-month NKTR stock forecast based on 33 Wall Street analysts shows a consensus price target of $132.83, with estimates ranging from $95 (bear case) to $185 (bull case). The median consensus rating is "Buy".
Should I buy NKTR stock?
Wall Street analysts are very optimistic on NKTR, with a "Buy" consensus rating and $132.83 price target (57.8% upside). 22 of 33 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NKTR price targets vary so much?
NKTR analyst price targets range from $95 to $185, a 68% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $132.83 consensus represents the middle ground.